Experimental: UVA Sterile Solution in conjunction with the UVAR® THERAKOS® CELLEX Photopheresis System
TREATMENT with THERAKOS® CELLEX Photopheresis System on two consecutive days every 2 weeks for the first 3 months; then once per month for following 9 months.
Drug: UVADEX® (methoxsalen) Sterile Solution in conjunction with the UVAR® THERAKOS® CELLEX Photopheresis
Extracorporeal Photopheresis (ECP)
Device: THERAKOS® CELLEX photopheresis system
UVAR® THERAKOS® CELLEX is an FDA-approved extra-corporeal photopheresis system
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
